Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2019

Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2019

Summary

GlobalData's Medical Devices sector report, “Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2019 provides an overview of Bioabsorbable Stents (BAS) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Bioabsorbable Stents (BAS) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Bioabsorbable Stents (BAS) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Bioabsorbable Stents (BAS) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Bioabsorbable Stents (BAS) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


  • Introduction
    • Bioabsorbable Stents (BAS) Overview
  • Products under Development
    • Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Under Development
      • Table Figure 1: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Under Development
      • Table Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Under Development
    • Bioabsorbable Stents (BAS) - Pipeline Products by Territory
      • Table Figure 2: Bioabsorbable Stents (BAS) - Pipeline Products by Territory
      • Table Bioabsorbable Stents (BAS) - Pipeline Products by Territory
    • Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
      • Table Figure 3: Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
      • Table Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
    • Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
      • Table Figure 4: Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
      • Table Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
    • Bioabsorbable Stents (BAS) - Ongoing Clinical Trials
      • Table Figure 5: Bioabsorbable Stents (BAS) - Ongoing Clinical Trials
      • Table Bioabsorbable Stents (BAS) - Ongoing Clinical Trials
  • Bioabsorbable Stents (BAS) - Pipeline Products under Development by Companies
    • Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development
      • Table Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development
    • Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
      • Table Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
  • Bioabsorbable Stents (BAS) Companies and Product Overview
    • Abbott Vascular Inc Company Overview
      • Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Second Generation Bioresorbable Vascular Scaffold - Product Status
        • Table Second Generation Bioresorbable Vascular Scaffold - Product Description
    • Amaranth Medical Inc Company Overview
      • Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table 80-micron MAGNITUDE Bioresorbable Scaffold - Product Status
        • Table 80-micron MAGNITUDE Bioresorbable Scaffold - Product Description
        • Table APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status
        • Table APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description
        • Table DEFIANCE Scaffold - Product Status
        • Table DEFIANCE Scaffold - Product Description
        • Table FORTITUDE Scaffold - Product Status
        • Table FORTITUDE Scaffold - Product Description
        • Table MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status
        • Table MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description
        • Table Second Generation FORTITUDE Scaffold - Product Status
        • Table Second Generation FORTITUDE Scaffold - Product Description
        • Table Amaranth Medical Inc - Ongoing Clinical Trials Overview
        • Table FORTITUDE Scaffold - Amaranth Endovascular Study of a Drug-eluting Bioresorbable Coronary Scaffold
        • Table FORTITUDE Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds – European Trial
        • Table APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial II
        • Table MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial III
    • Arterius Ltd Company Overview
      • Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Arteriosorb Absorbable Drug-Eluting Scaffold - Product Status
        • Table Arteriosorb Absorbable Drug-Eluting Scaffold - Product Description
    • Biosensors International Group Ltd Company Overview
      • Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Sparrow Drug Eluting Stent System - Product Status
        • Table Sparrow Drug Eluting Stent System - Product Description
    • Biosten, LLC Company Overview
      • Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biodegradable Endovascular Implant - Product Status
        • Table Biodegradable Endovascular Implant - Product Description
    • Biotronik AG Company Overview
      • Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
        • Table Magmaris Bioresorbable Magnesium Scaffold - Product Status
        • Table Magmaris Bioresorbable Magnesium Scaffold - Product Description
        • Table Magmaris Bioresorbable Magnesium Scaffold - 3rd Generation - Product Status
        • Table Magmaris Bioresorbable Magnesium Scaffold - 3rd Generation - Product Description
        • Table Biotronik AG - Ongoing Clinical Trials Overview
        • Table Magmaris Bioresorbable Magnesium Scaffold - A Sirolimus Eluting Bioresorbable Magnesium Stent for Treatment of Coronary Bifurcation Lesions: The BIFSORB Pilot Study II
        • Table Magmaris Bioresorbable Magnesium Scaffold - BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-II
        • Table Magmaris Bioresorbable Magnesium Scaffold - BIOTRONIKS - Acute Performance of a Drug Eluting Absorbable Metal Scaffold (DREAMS 2G) in Patients with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-III
        • Table Magmaris Bioresorbable Magnesium Scaffold - Biotroniks - Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris- Registry: BIOSOLVE-IV
        • Table Magmaris Bioresorbable Magnesium Scaffold - BIOTRONIKS-Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris (BIOSOLVE)-IV Magmaris Swiss Satellite Registry
        • Table Magmaris Bioresorbable Magnesium Scaffold - Coronary Artery Healing Process after Bioresorbable Scaffold in Patients with Non-ST-segment Elevation Myocardial Infarction (NSTEMI)
        • Table Magmaris Bioresorbable Magnesium Scaffold - Magnesium-based Bioresorbable Scaffold and Vasomotor Function in Patients with Acute ST Segment Elevation Myocardial Infarction
        • Table Magmaris Bioresorbable Magnesium Scaffold - Optical Coherence Guided Treatment of Stsegment Elevation Myocardial Infarction with the Drug-eluting Resorbable Magnesium Scaffold: The BEST- MAG Multicentre Study (Belgian ST-segment Elevation Myocardial Infarction Treatment with Resorbable Magnesium Scaffold)
        • Table Magmaris Bioresorbable Magnesium Scaffold - Optical Coherence Tomography Evaluation of Bioabsorbable Vascular Scaffold Technique with Magmaris
        • Table Magmaris Bioresorbable Magnesium Scaffold - Prospective Observational Registry of Patients with a Bioabsorbable Magnesium Stent Implant -MAGMARIS- in Usual Clinical Practice
        • Table Magmaris Bioresorbable Magnesium Scaffold - Retrospective, Observational Register to Investigate the Procedural and Post Procedural Implantation of Bioabsorbable Magnesium Scaffolds MAGMARIS (MAGIC Registry)
        • Table Magmaris Bioresorbable Magnesium Scaffold - Scaffold Implantation in Emilia-Romagna
        • Table Magmaris Bioresorbable Magnesium Scaffold - 3rd Generation - BIOTRONIK - Safety and Clinical Performance of the - Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries
    • Biotronik SE & Co KG Company Overview
      • Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
        • Table AMS-2 - Product Status
        • Table AMS-2 - Product Description
    • Boston Scientific Corp Company Overview
      • Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Fully Resorbable Drug-Eluting Scaffold System - Product Status
        • Table Fully Resorbable Drug-Eluting Scaffold System - Product Description
        • Table SYNERGY DES 4.5/5.0 - Product Status
        • Table SYNERGY DES 4.5/5.0 - Product Description
        • Table Boston Scientific Corp - Ongoing Clinical Trials Overview
        • Table SYNERGY DES 4.5/5.0 - A U.S. Post-approval Study of the SYNERGY 4.50/5.00 mm Everolimuseluting Platinum Chromium Coronary Stent System (Evolve 4.5/5.0)
        • Table Fully Resorbable Drug-Eluting Scaffold System - Fully Absorbable Scaffold Feasibility Study
    • Cardionovum GmbH Company Overview
      • Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table CARDIOSORB - Product Status
        • Table CARDIOSORB - Product Description
    • Cordis Corp Company Overview
      • Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table SymBio Pimecrolimus/Paclitaxel-eluting Stent - Product Status
        • Table SymBio Pimecrolimus/Paclitaxel-eluting Stent - Product Description
    • HangZhou HuaAn Biotechnology Co., Ltd. Company Overview
      • HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
        • Table HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Xinsorb BRS - Product Status
        • Table Xinsorb BRS - Product Description
    • Icon Interventional Systems, Inc. Company Overview
      • Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biosorb Pediatric Dissolving Stent - Product Status
        • Table Biosorb Pediatric Dissolving Stent - Product Description
    • Japan Stent Technology Co., Ltd. Company Overview
      • Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Japan Stent Technology Co., Ltd. Bioabsorbable Stent - Product Status
        • Table Japan Stent Technology Co., Ltd. Bioabsorbable Stent - Product Description
    • Kyoto Medical Planning Co Ltd Company Overview
      • Kyoto Medical Planning Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Kyoto Medical Planning Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Igaki-Tamai Coronary Stent - Product Status
        • Table Igaki-Tamai Coronary Stent - Product Description
    • Lifetech Scientific (Shenzhen) Co Ltd Company Overview
      • Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System - Product Status
        • Table IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System - Product Description
        • Table Lifetech Scientific (Shenzhen) Co Ltd - Ongoing Clinical Trials Overview
        • Table IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System - A First-in-man Study of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
        • Table IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System - A Prospective, Nonrandomized, Open-label, Non-comparative, First-in-Man Study to Evaluate the Feasibility and Safety of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System
    • Manli Cardiology Ltd Company Overview
      • Manli Cardiology Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Manli Cardiology Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table MIRAGE - Product Status
        • Table MIRAGE - Product Description
    • Micell Technologies Inc Company Overview
      • Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Bioresorbable Scaffold (BRS) - Product Status
        • Table Bioresorbable Scaffold (BRS) - Product Description
        • Table MiStent SES - Product Status
        • Table MiStent SES - Product Description
        • Table Micell Technologies Inc - Ongoing Clinical Trials Overview
        • Table MiStent SES - A Prospective, Single-blinded, Multi-center, Randomized, Controlled, Registered Clinical Trial on the Efficacy and Safety of Sirolimus-eluting Stent (MiStent System) in the Treatment of Patients with Coronary Heart Disease
        • Table MiStent SES - MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) Optical Coherence Tomography (OCT)
        • Table MiStent SES - Multicenter Randomized Study of the MiStent Sirolimus Eluting Absorbable Polymer Stent System (MiStent SES) for Revascularization of Coronary Arteries
        • Table MiStent SES - Multicenter Randomized Study of the Mistent Sirolimus Eluting Absorbable Polymer Stent System (MT005) for Revascularization of Coronary Arteries
    • Michigan Technological University Company Overview
      • Michigan Technological University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Michigan Technological University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Bioabsorbable Stent - Product Status
        • Table Bioabsorbable Stent - Product Description
    • MicroPort Scientific Corp Company Overview
      • MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Firefalcon Bioresorbable Device - Product Status
        • Table Firefalcon Bioresorbable Device - Product Description
        • Table Firesorb - Product Status
        • Table Firesorb - Product Description
        • Table MicroPort Scientific Corp - Ongoing Clinical Trials Overview
        • Table Firesorb - A First-in-man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease: FUTURE-I
        • Table Firesorb - A Prospective Multicenter Single-arm Clinical Trial Assessing the Safety and Effectiveness of Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold for the Treatment of Coronary Artery Disease: FUTURE III
        • Table Firesorb - A Randomized Trial of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease: FUTURE-II
    • Minvasys SAS Company Overview
      • Minvasys SAS Pipeline Products & Ongoing Clinical Trials Overview
        • Table Minvasys SAS Pipeline Products & Ongoing Clinical Trials Overview
        • Table Nile LM SIR Sirolimus Eluting Intracoronary Stent - Product Status
        • Table Nile LM SIR Sirolimus Eluting Intracoronary Stent - Product Description
    • MIV Therapeutics Inc Company Overview
      • MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Smart-1 DES - Product Status
        • Table Smart-1 DES - Product Description
        • Table Smart-4 DES - Product Status
        • Table Smart-4 DES - Product Description
    • NanoCoeur, Inc. Company Overview
      • NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Nanocoating Cardiac Stent - Product Status
        • Table Nanocoating Cardiac Stent - Product Description
    • North Carolina State University Company Overview
      • North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview
        • Table North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biodegradable Metal Stent - Product Status
        • Table Biodegradable Metal Stent - Product Description
    • Northwestern University Company Overview
      • Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Liquid Cast Drug-Eluting Biodegradable Stent - Product Status
        • Table Liquid Cast Drug-Eluting Biodegradable Stent - Product Description
    • OrbusNeich Company Overview
      • OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview
        • Table OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview
        • Table Cura Stent - Product Status
        • Table Cura Stent - Product Description
        • Table Sirolimus-Eluting Absorbable Vascular Scaffold - Product Status
        • Table Sirolimus-Eluting Absorbable Vascular Scaffold - Product Description
    • Pediastent LLC Company Overview
      • Pediastent LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Pediastent LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Pediatric Bioresorbable Stent - Product Status
        • Table Pediatric Bioresorbable Stent - Product Description
    • QualiMed Innovative Medizinprodukte GmbH Company Overview
      • QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biodegradable Coronary Stent - Product Status
        • Table Biodegradable Coronary Stent - Product Description
    • REVA Medical Inc Company Overview
      • REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Status
        • Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Description
        • Table REVA Medical Inc - Ongoing Clinical Trials Overview
        • Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Expanded FANTOM II Clinical Study
        • Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Pilot Study of the REVA Sirolimus- Eluting Bioresorbable Coronary Scaffold
        • Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Post Market Study of the FANTOM Sirolimus-eluting Bioresorbable Coronary Scaffold
        • Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Safety and Performance Study of the FANTOM Sirolimus-eluting Bioresorbable Coronary Scaffold
        • Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Vascular Healing Pattern, Vasoreactivity, and Quality of Life in Patients with ST Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention with Sirolimus Eluting FANTOM Bioresorbable Vascular Scaffold with Long Term Clinical, Near Infrared Spectroscopy and Optical Coherence Tomography Follow-up: A FANTOM STEMI Pilot Study
    • S3V Vascular Technologies Company Overview
      • S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview
        • Table S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview
        • Table 3V Avatar - Product Status
        • Table 3V Avatar - Product Description
    • Tepha Inc Company Overview
      • Tepha Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Tepha Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table TephaFLEX Absorbable Coronary Stent - Product Status
        • Table TephaFLEX Absorbable Coronary Stent - Product Description
    • University of Alabama at Birmingham Company Overview
      • University of Alabama at Birmingham Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Alabama at Birmingham Pipeline Products & Ongoing Clinical Trials Overview
        • Table Endothelium Nanomatrix Coated Stent - Product Status
        • Table Endothelium Nanomatrix Coated Stent - Product Description
    • University of Florida Company Overview
      • University of Florida Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Florida Pipeline Products & Ongoing Clinical Trials Overview
        • Table Nanocomposite Drug Eluting Stent - Product Status
        • Table Nanocomposite Drug Eluting Stent - Product Description
    • University of Strathclyde Company Overview
      • University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview
        • Table Magnesium Alloy Stent - Product Status
        • Table Magnesium Alloy Stent - Product Description
    • VasoTech Inc. Company Overview
      • VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table PowerStent Absorb DES - Product Status
        • Table PowerStent Absorb DES - Product Description
    • Xenogenics Corporation Company Overview
      • Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview
        • Table Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview
        • Table Ideal BioStent - First Generation - Product Status
        • Table Ideal BioStent - First Generation - Product Description
        • Table Ideal BioStent - Second Generation - Product Status
        • Table Ideal BioStent - Second Generation - Product Description
        • Table Whisper Coronary Stent System - Product Status
        • Table Whisper Coronary Stent System - Product Description
  • Bioabsorbable Stents (BAS)- Recent Developments
    • Nov 06, 2019: Final five unpublished late-breaking clinical trial results announced at VIVA19
    • Oct 23, 2019: Boston Scientific announces results for third quarter 2019
    • Sep 20, 2019: Terumo to increase production capacity for alliance business
    • Aug 29, 2019: MicroPort announces interim results for the six months ended June 30, 2019
    • Aug 28, 2019: Boston Scientific Celebrates 15th Anniversary in Costa Rica
    • Aug 05, 2019: REVA receives additional interim funding
    • Jul 24, 2019: Boston Scientific announces results for second quarter 2019
    • Jul 08, 2019: Terumo invests 26 Million Euro in new production lines for its Belgian Facility
    • Jul 03, 2019: Mr. Rodrigo Perez Estrada Joins MicroPort as vice president global branding
    • Jun 24, 2019: Boston Scientific Galway expands in to new facility
    • Jun 07, 2019: New data confirms future of Resorbable Magnesium Scaffolds
    • May 21, 2019: Terumo appoints EU based Subsidiary's Associate as the Newest Terumo Fellow
    • Apr 24, 2019: Boston Scientific announces results for first quarter 2019
    • Mar 28, 2019: MicroPort announces annual results for 2018
    • Mar 24, 2019: REVA receives interim funding commitment and announces leadership changes
    • Mar 05, 2019: Early Resorption, Low Complications: Late Breaker at CRT 2019 shows safety and efficacy of Magmaris
    • Feb 26, 2019: Terumo to construct new facilities at its Vietnamese factory -15 billion yen investment to strengthen interventional therapeutic related production
    • Feb 15, 2019: BRAVO BIDCO: Update on the proposed acquisition of BTG
    • Feb 06, 2019: Boston Scientific announces results for fourth quarter and full year 2018
    • Feb 05, 2019: REVA announces reduction in force
    • Jan 22, 2019: Neovasc Announces Dismissal of Claim brought by Edwards Lifesciences
    • Jan 15, 2019: Boston Scientific, Edwards Lifesciences agree to global litigation settlement
    • Jan 08, 2019: Boston Scientific announces preliminary unaudited sales for the fourth quarter and full year 2018
    • Jan 07, 2019: Reva expands geographic footprint to seven new countries
    • Jan 04, 2019: REVA Medical announces that Leigh Elkolli promoted to chief financial officer
    • Jan 03, 2019: Leigh Elkolli promoted to chief financial officer at Reva Medical
    • Dec 26, 2018: Mr. Noboru Shimizu joined MicroPort CRM as Vice-President, Country Manager Japan, and Head of Commercial Operations of MicroPort CRM Japan
  • Appendix
    • Methodology
      • Table Glossary
    • About GlobalData
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook